This content is intended for healthcare professionals only.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.
Login
Don't have an account yet? Register now
Lost your password? Reset password
OR
Login with DocCheck Login with Linkedin
Access as a guest
Choose Language
English
English
https://beigenemedical.info/search/WM/
Italian
https://beigenemedical.info/it/search/WM/
French
https://beigenemedical.info/fr/search/WM/
Spanish
https://beigenemedical.info/es/search/WM/
German
https://beigenemedical.info/de/search/WM/
I am not a Healthcare Professional

Please login or register for full access

Register
Already registered? Login
Skip to content
Choose Language
English
English
English
Italian
Italian
French
French
Spanish
Spanish
German
German
Login / Register
  • Congresses
    • Congress Calendar
    • Virtual Congress
  • BeiGeneius
  • Pipelines
Choose Language
English
English
English
Italian
Italian
French
French
Spanish
Spanish
German
German

WM

Waldenström's macroglobulinemia is a rare, low-grade B-cell lymphoproliferative malignancy
All Types
All Types
Reading
reading
Slide-Kit
slidekit
Video
video
Latest
Latest
latest
Oldest
oldest
All Types
All Types
Reading
reading
Slide-Kit
slidekit
Video
video
Latest
Latest
latest
Oldest
oldest
Suggested:
CLL
EHA
ESMO
Hematologic malignancies
Solid tumor
WM
BeiGene

BSH 2022 Satellite Symposium: Emerging Options in the Treatment of Waldenströms Macroglobulinaemia

The Satellite Symposium at BSH 2022 provided expert insights into treatment options in WM, the emerging role of BTKis in WM, and BTKi-associated toxicities and their management.

Reading
26 Apr 2022
Waldenström's macroglobulinemia
BSH
Zanubrutinib
Please login or register to access the download
memo

Memo inOncology - ASH 2021 congress report

Report on updates in the treatment of B-cell malignancies presented at ASH 2021.

Reading
26 Apr 2022
ASH
Chronic lymphocytic leukemia
Hematologic malignancies
Please login or register to access the download
BeiGene

BeiGene clinical pipeline for hematologic malignancies

BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene hematology pipeline and clinical trials.

Reading
25 Mar 2022
BeiGene
Pipeline
Hematologic malignancies
Please login or register to access the download
BeiGene

Zanubrutinib MoA slide kit

Zanubrutinib (BGB-3111) is a Bruton’s tyrosine kinase inhibitor (BTKi), currently being evaluated in a broad late-stage clinical trials program globally to treat various B-cell malignancies.

Slide-Kit
11 Jan 2022
Zanubrutinib
Hematologic malignancies
Please login or register to access the download
memo

Memo inHaematology - ASCO, EHA and ICML 2021 congress report

Report on targeted and immune-directed therapies in B-cell malignancies presented at ASCO, EHA and ICML 2021.

Reading
15 Dec 2021
EHA
ASCO
ICML
Load More

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.

As part of scientific exchange, BeiGene is providing the most recent abstract(s) accepted by the referenced scientific congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of BeiGene products.​

  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Legal notice

waldenstroms.info

memo inOncology

© BeiGene 2022. All rights reserved.   |   Cookie Settings

You're now leaving the website beigenemedical.info

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave beigenemedical.info website. The link will take you to another BeiGene website, the content of which is subject to the locally applicable laws and regulations.

BeGene Switzerland GmbH makes no representation that the information provided on the website is suitable or available for use or access in locations outside the country for which the website is intended.

Please ensure that you belong to the target group of the content provided on the linked website and that your access to it complies with the applicable laws and regulations.

No, I want to go back Yes, I would like to continue

You're now leaving the website beigenemedical.info

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave beigenemedical.info website. The link will take you to a website owned and operated by an independent party over which BeiGene Switzerland GmbH has no control or influence (“third-party website”).​

BeiGene Switzerland GmbH makes no representation that information on the third-party website is appropriate or available for use or access in locations outside the country for which the third-party website is intended. Therefore, BeiGene Switzerland GmbH declines any responsibility for third-party information. BeiGene Switzerland GmbH makes no representation regarding the data usage policies of the third party website and declines any responsibility for the use of personal data by the operator of the third-party website. Please ensure that you belong to the intended audience of the content provided on third-party website and that your access to it complies with the applicable laws and regulations.

Do you really want to leave the beigenemedical.info website?

No, I want to go back Yes, I would like to continue